ANDA 71484, held by Hospira. Vincristine Sulfate.
As of Nov 21, 2026, ANDA 71484 (Vincristine Sulfate Pfs), held by Hospira, was first approved by FDA on Apr 19, 1988, with 27 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 19, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vincristine Sulfate Pfs1MG/ML · injectable;injection | Vincristine Sulfate | Rx |
| Dec 17, 2025 | Supplement 51Labeling · Standard review | Approved | None posted |
| Sep 22, 2021 | Supplement 46Labeling · Standard review | Approved | None posted |
| Jan 14, 2021 | Supplement 47Labeling · Standard review | Approved | None posted |
| Sep 23, 2019 | Supplement 44Labeling · Standard review | Approved | None posted |
| Apr 24, 2015 | Supplement 39Manufacturing | Approved | None posted |
| Aug 5, 2014 | Supplement 42Labeling · Standard review | Approved | |
| May 7, 2013 | Supplement 41Labeling · Standard review | Approved | None posted |
| Jan 23, 2012 | Supplement 38Labeling | Approved | None posted |
| Jan 25, 2007 | Supplement 31Labeling | Approved | None posted |
| Sep 25, 2001 | Supplement 25Labeling | Approved | None posted |
| May 14, 2001 | Supplement 24Manufacturing | Approved | None posted |
| Aug 8, 2000 | Supplement 22Manufacturing | Approved | None posted |
| May 18, 2000 | Supplement 21Manufacturing | Approved | None posted |
| May 12, 2000 | Supplement 20Manufacturing | Approved | None posted |
| Apr 16, 1997 | Supplement 12Manufacturing | Approved | None posted |
| Apr 7, 1997 | Supplement 17Manufacturing | Approved | None posted |
| Jul 2, 1996 | Supplement 16Manufacturing | Approved | None posted |
| Nov 7, 1995 | Supplement 14Labeling | Approved | None posted |
| Apr 28, 1995 | Supplement 13Manufacturing | Approved | None posted |
| Jul 1, 1994 | Supplement 11Labeling | Approved | None posted |
| Nov 3, 1992 | Supplement 10Labeling | Approved | None posted |
| Apr 6, 1992 | Supplement 4Manufacturing | Approved | None posted |
| Apr 6, 1992 | Supplement 3Manufacturing | Approved | None posted |
| Jul 16, 1991 | Supplement 6Manufacturing | Approved | None posted |
| Apr 4, 1990 | Supplement 5Labeling | Approved | None posted |
| Jul 14, 1989 | Supplement 2Manufacturing | Approved | None posted |
| Jun 20, 1988 | Supplement 1Labeling | Approved | None posted |
| Apr 19, 1988 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters